Correction: Interferon β-1a for the treatment of Ebola virus disease: A historically controlled, single-arm proof-of-concept trial.

[This corrects the article DOI: 10.1371/journal.pone.0169255.].

There is an error in affiliation 3 for author Darren P. Baker. Affiliation 3 should be: Sanofi Genzyme, Cambridge, Massachusetts, United States of America.

There is an error in the caption for Fig 2. Please see the complete, correct Fig 2 caption here. The publisher apologizes for these errors.

Fig 2

IFN β-1a treatment effect on survival of patients with EVD.

Survival curves for patients with EVD receiving supportive care only (n = 21) (solid line) or supportive care plus IFN β-1a treatment (n = 9) (dashed line). Survival was calculated from the date of consent for those receiving IFN β-1a treatment and date of admission for those in the control cohort, to the date of death. Survival plots were based on Kaplan-Meier estimates and the plots were compared using the log rank test (p = 0.026).